NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns
This article was originally published in RPM Report
Executive Summary
Legislators are urging the National Institutes of Health to use intellectual property levers to put pressure on prescription drug pricing. NIH has historically been reluctant to play the role of the price police – and it still is.
You may also be interested in...
Reference Pricing Clauses In US COVID-19 Contracts Leave Drug Industry Vulnerable
Innovation and price controls can coexist in the United States, COVID-19 contracts show. But drug pricing experts also acknowledge the unique circumstances of COVID-19 could make such contracts hard to replicate and argue that reference-pricing strategies may have limited ability to lower prices.
Trump’s Legacy Versus ‘March In’ Rights
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.
‘March In’ Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: